NCT06100237: Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study)

Sponsor: Carl Ola Landgren, MD, PhD. Phase: PHASE2. Conditions: Multiple Myeloma